Teligent Announces Strategic Review
In response to inbound interest and evolving market conditions both in
“In 2014, we launched our strategy to invest in topical, injectable, complex, and ophthalmics or what we refer to as ‘TICO’. We remain committed to our TICO strategy, but recognize that in the face of a changing marketplace and inbound interest in the assets we developed, it’s in our shareholders’ best interest to explore options to monetize these assets. If successful, our intent is to use the proceeds from such transactions to pay down debt and continue our efforts to realize the full potential of our future US sterile-injectable manufacturing capabilities, pending
There is no defined timeline and there can be no assurance this strategic review will result in the completion of any course of action. The Company does not intend to comment further unless a specific initiative is approved by the Board of Directors, the review process is concluded, or disclosure is required.
Source: Teligent, Inc.